Precision BioSciences Files Fourth Patent Lawsuit Against Cellectis | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Precision BioSciences today said it has filed a fourth lawsuit against Cellectis and a number of its affiliates alleging patent infringement.

The company filed its lawsuit in US District Court for the Eastern District of North Carolina claiming Cellectis infringes on US Patent No. 8,124,369, which relates to Precision Bio's Directed Nuclease Editor genome engineering technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.